| scholarly article | Q13442814 |
| P2093 | author name string | Stephen C Pflugfelder | |
| Gary N Foulks | |||
| Joseph Tauber | |||
| Laurie D Barber | |||
| P433 | issue | 10 | |
| P921 | main subject | cyclosporine | Q367700 |
| eye disease | Q3041498 | ||
| P304 | page(s) | 1790-1794 | |
| P577 | publication date | 2005-10-01 | |
| P1433 | published in | Ophthalmology | Q7098109 |
| P1476 | title | Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years | |
| P478 | volume | 112 |
| Q41442733 | A comparative review of Haute Autorité de Santé and National Institute for Health and Care Excellence health technology assessments of Ikervis® to treat severe keratitis in adult patients with dry eye disease which has not improved despite treatment |
| Q54222666 | A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. |
| Q92236581 | A study of refractory cases of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops |
| Q92442286 | Advances in dry eye disease treatment |
| Q35863016 | Anti-inflammatory effects of hinokitiol on human corneal epithelial cells: an in vitro study |
| Q40469419 | Anti-inflammatory effects of intranasal cyclosporine for allergic rhinitis in a mouse model. |
| Q39151688 | Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature |
| Q90403137 | Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study |
| Q36269034 | Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine |
| Q57378488 | Current and emerging therapy of dry eye disease. Part A: pharmacological modalities |
| Q37781669 | Current insights into ocular graft-versus-host disease |
| Q45012706 | Cyclosporine 0.05% ophthalmic emulsion for the treatment of radiation-associated dry eye in children |
| Q35570541 | Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence |
| Q37126861 | Effect of topical 0.05% cyclosporine A on corneal endothelium in patients with dry eye disease. |
| Q34208099 | Effects of mycophenolate mofetil on proliferation and mucin-5AC expression in human conjunctival goblet cells in vitro |
| Q51611085 | Electronic enhancement of tear secretion. |
| Q33585580 | Enhanced Tearing by Electrical Stimulation of the Anterior Ethmoid Nerve |
| Q35805082 | Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED). |
| Q90356527 | Hydrophobic drug adsorption loss to syringe filters from a perspective of drug delivery |
| Q33686673 | Korean guidelines for the diagnosis and management of dry eye: development and validation of clinical efficacy. |
| Q24635929 | Lacritin, a novel human tear glycoprotein, promotes sustained basal tearing and is well tolerated. |
| Q21092925 | Long-term topical cyclosporin A therapy in Thygeson's superficial punctate keratitis: a case report |
| Q58599953 | Matrix Metalloproteinase 9 Point-of-Care Immunoassay Result Predicts Response to Topical Cyclosporine Treatment in Dry Eye Disease |
| Q36964677 | Next-generation calcineurin inhibitors for ophthalmic indications |
| Q36182937 | Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model |
| Q81551290 | Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease |
| Q57381957 | Ocular surface reconstruction: recent innovations, surgical candidate selection and postoperative management |
| Q53836361 | One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease. |
| Q52608828 | Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye. |
| Q38184630 | Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis |
| Q37079081 | Pharmacological management of dry eye in the elderly patient |
| Q91905513 | Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease |
| Q38076460 | Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions. |
| Q36569538 | Randomized, Multicenter, Double-Blind Study of the Safety and Efficacy of 1%D-3-Hydroxybutyrate eye drops for Dry Eye Disease |
| Q38584878 | Recommendations for the treatment of Sjögren's syndrome |
| Q36478996 | Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits |
| Q38711144 | Safety of treatments for primary Sjögren's syndrome |
| Q37070035 | Short term effects of topical cyclosporine and viscoelastic on the ocular surfaces in patients with dry eye |
| Q36864045 | The Effect of Autologous Platelet Lysate Eye Drops: An In Vivo Confocal Microscopy Study |
| Q38925320 | The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review |
| Q38462657 | The effect of additional topical cyclosporine or vitamin A on the ocular surface during antiglaucoma medication administration |
| Q44498935 | Topical and systemic medications for the treatment of primary Sjögren's syndrome. |
| Q90093016 | Topical cyclosporine A therapy for dry eye syndrome |
| Q42925094 | Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression |
| Q34206399 | Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. |
| Q50025206 | Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program. |
| Q91632324 | Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease |
| Q37236096 | Treatment of chronic dry eye: focus on cyclosporine |
| Q30249011 | Treatment of primary Sjögren syndrome |
Search more.